Tesar V
Nefrologické oddĕlení I. interní kliniky 1. lékarské fakulty UK a VFN, Praha.
Vnitr Lek. 2003 May;49(5):365-9.
Progression of chronic nephropathies can be significantly retarded by optimal control of blood pressure. To achieve target blood pressure combined treatment is usually necessary in patients with chronic nephropathies. Drugs interfere with the renin-angiotensin-aldosterone system (angiotensin converting enzyme inhibitors and angiotensin antagonists) have as compared with other antihypertensive agents with a comparable blood pressure control a more marked renoprotective effect and are renoprotective also in normotensive microalbuminuric patients with diabetic nephropathy and in proteinuric patients with non-diabetic nephropathies. Treatment with angiotensin converting enzyme inhibitors and angiotensin antagonists should be started as soon as possible and should be lifelong.
通过优化血压控制可显著延缓慢性肾病的进展。对于慢性肾病患者，通常需要联合治疗以达到目标血压。与其他具有相似血压控制效果的抗高血压药物相比，作用于肾素 - 血管紧张素 - 醛固酮系统的药物（血管紧张素转换酶抑制剂和血管紧张素拮抗剂）具有更显著的肾脏保护作用，并且对糖尿病肾病的血压正常的微量白蛋白尿患者以及非糖尿病肾病的蛋白尿患者也有肾脏保护作用。血管紧张素转换酶抑制剂和血管紧张素拮抗剂治疗应尽早开始且应终身进行。
